Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% Higher - Time to Buy?

Key Points

• Structure Therapeutics (NASDAQ:GPCR) experienced a 5.8% increase in trading, reaching a last traded value of $26.76, although trading volume was down 59% from average levels.
• Analysts have mixed outlooks, with a few upgrades to "strong-buy" and numerous price target adjustments, resulting in an average rating of "Buy" and a target price of $68.67.
• The company reported a loss of ($0.36) EPS in its last earnings, missing the consensus estimate, and analysts predict an EPS of -0.82 for the fiscal year.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) traded up 5.8% on Tuesday . The stock traded as high as $26.45 and last traded at $26.76. 376,354 shares were traded during mid-day trading, a decline of 59% from the average session volume of 908,369 shares. The stock had previously closed at $25.30.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GPCR. HC Wainwright decreased their price objective on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. JMP Securities decreased their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Lifesci Capital upgraded Structure Therapeutics to a "strong-buy" rating in a research note on Monday, September 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, June 23rd. Finally, Guggenheim decreased their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Structure Therapeutics currently has an average rating of "Buy" and an average price target of $68.67.

Structure Therapeutics Price Performance

The firm has a 50 day moving average of $19.90 and a two-hundred day moving average of $20.80. The stock has a market cap of $1.61 billion, a PE ratio of -26.67 and a beta of -1.88.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, equities analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vestal Point Capital LP lifted its stake in Structure Therapeutics by 3.7% in the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock valued at $30,967,000 after buying an additional 63,990 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Structure Therapeutics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company's stock valued at $32,939,000 after buying an additional 106,389 shares during the last quarter. Orbimed Advisors LLC lifted its stake in Structure Therapeutics by 49.5% in the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company's stock valued at $24,873,000 after buying an additional 397,272 shares during the last quarter. Readystate Asset Management LP lifted its stake in Structure Therapeutics by 129.9% in the first quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock valued at $8,330,000 after buying an additional 271,899 shares during the last quarter. Finally, Pacific Heights Asset Management LLC purchased a new stake in Structure Therapeutics in the second quarter valued at approximately $9,540,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.